Idronoxil novel formulation - Noxopharm

Drug Profile

Idronoxil novel formulation - Noxopharm

Alternative Names: NOX-66

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Noxopharm
  • Class Antineoplastics; Hormones; Isoflavones; Small molecules
  • Mechanism of Action Caspase stimulants; NADH oxidase inhibitors; Proto oncogene protein c-akt inhibitors; X-linked inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 03 Mar 2017 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Refractory metastatic disease, Second-line therapy or greater) in USA (unspecified route)
  • 03 Mar 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Refractory metastatic disease, Second-line therapy or greater) in USA (NCT02941523)
  • 31 Jan 2017 Royal North Shore Hospital plans a phase I trial for Prostate cancer (Metastatic disease, Second-line therapy or greater) in Australia (Suppository) (NCT03041285)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top